Abstract: Extending virtual screening approaches to deal with multi-target drug design and polypharmacology is an increasingly important aspect in drug design. In light of this, the concept of accessible chemical space and its exploration should be reviewed. The great advantages of re-using drugs with safe pharmacological profiles with favourable pharmacokinetic properties highlights drug repositioning as a valid alternative to rational drug design, massive drug development efforts, and high-throughput screening, especially when supported by in silico techniques. Here, we discuss some of the advantages of multi-target approaches, and we review some significant examples of their application in the last decade to that well known class of pharmaceutical targets, the G-protein coupled receptors.
INTRODUCTION
Drug discovery is a highly interdisciplinary endeavour that involves a multitude of specialty areas and which can be characterized in multiple steps. Generally, it starts with target identification and validation, followed by lead identification and optimization, then progressing to pre-clinical studies on animals and finally clinical trials in humans. Nonetheless, the drug design philosophy has changed dramatically over the last 40 years. The first paradigm in the golden age of rational design was driven by the first quantitative structureactivity relationships (QSARs) which aimed to suggest the synthesis of a small number of compounds, properly selected and possibly endowing high potency and selectivity towards particular targets. However, during the early 1990s, this tendency was reversed by new developments in the field of high-throughput screening (HTS) [1] and combinatorial chemistry [2] . These techniques enabled medicinal chemists to synthesize large libraries of chemical compounds and to screen them in a fast and efficient manner. However, drug design and new lead identification is becoming an increasingly time-consuming and costly process. It has recently been estimated that bringing a new drug to the pharmaceutical market costs about 800 million US$. The FDA approved just 30 novel new drugs in 2011, and this number is rather typical of the previous few years (Fig. 1) . Twelve of these new molecular entities (40%) were indeed identified as "first-in-class," meaning drugs which use a new and unique mechanism of action for treating a medical condition.
It is evident that the biological and chemical target spaced are quite different. For example, it has been estimated that the number of naturally occurring proteins is 250000, while the number of organic compounds with molecular weight (MW) < 2 KDa is greater than 10 60 [3] (Fig. 2) . So drug discovery might be considered as looking for a needle in a haystack, or a rare star in the "chemical universe". Furthermore, low hit rates in conjunction with a high level of false positives have been observed for particular biological targets, and promising lead structures identified by HTS, QSAR, structure-based drug design, combinatorial chemistry, high content in vitro screening often encounter issues with bioavailability and toxicity at a later stage of development. Finally, combinatorial synthesis has been criticized for generating highly similar chemical structures with limited diversity, thus restricting the chemical space that is sampled in each project. Thus, despite our growing knowledge of molecular biology and the rising sums of money that have been invested into expanding drug pipelines, the rate of new drug approvals has remained painfully stagnant.
Indeed, drug profiling might sometimes be difficult or misleading because selectivity problems often occur or because agonism might be observed in the design of antagonists. The same can also be said of orthosteric/allosteric modulators. The concept of one drug fits all is now being replaced by the notions polypharmacology and drug repositioning, with more than 30 drugs having been tested against more than 40 novel secondary targets based on promiscuity predictions in recent years. According to this evidence, the idea of one drug acting on a single target has to be significantly reviewed. However, this raises several new questions, such as how to tailor molecular entities as multi-target drugs, how many of them are clinically used, and what is the improvement in their pharmacokinetic profiles with respect to classical drugs?
Here, we discuss these topics with respect to a specific class of biological targets, the G-Protein coupled receptors (GPCRs). GPCRs regulate nearly all physiological processes. They are the focus of intense study by both academia and industry, and they comprise major targets in drug discovery efforts. Many clinically effective drugs targeted toward specific GPCRs exhibit activity across multiple receptors. Although a lack of selectivity can increase off-target drug actions that result in toxicity, surprisingly many clinically effective drugs, especially those that work in the central nervous system (CNS), appear to exert superior clinical actions via the modulation of many GPCRs (i.e., they are "magic shotguns"). This effect of drug polypharmacology (i.e., side-effect liability versus enhanced efficacy) suggests that efficient but comprehensive approaches to define sites of drug action(s) at GPCRs are essential [4] . Here we will show the application of the classical virtual screening and the polypharmacology tools for target prediction to GPCRs.
CLASSICAL VIRTUAL SCREENING
In the past, finding new leads often involved starting from in vitro assays of diverse natural products, or even just plain serendipity. More recently, approaches such as "me too" variants, peptide-mimetics, pro-and soft drugs, and high-throughput screening (HTS), computer-aided or in silico drug design, have all been used to reduce the size of the chemical "haystack". In addition to these approaches, the selected optimization of side activities (SOSA) represents an alternative, and often low-cost, route to drug-like hits because the SOSA approach can transform a side activity into a main one, as demonstrated in several successful cases [5] (i.e. Diazepam, a tranquilizer, optimized into CI-1044, a phosphodiesterase inhibitor [6] ).
Nowadays, modern drug discovery depends heavily on computational methods, and these can significantly affect the success of a research program (Fig. 3) . In silico methods can be used to study (a) targets using protein and DNA sequences, genomes, networks or pathways and even tissues and organs such as the virtual liver, (b) small molecules such as those that are not polymers of amino acids or nucleic acids, and (c) complexes of small molecules with target proteins, DNA, or RNA. Based on these classifications, in silico techniques have been used in many ways, for example to analyze the similarity between small molecules or their targets, and to perform pharmacophore based modeling and screening, homology modeling, molecular dynamics (MD) simulation, and data mining of genomes or small molecule databases [7] .
From the early stages of the drug design discovery process to new lead identification, in silico methods may be used to perform the rapid screening of huge libraries of compounds to identify virtual hits which can then be purchased or synthesized, and hence verified experimentally. In silico methods may also be used to improve physicochemical properties of lead compounds (hit-to-lead optimization) and selectivity optimization. The growth of publicly accessible chemical databases has helped medicinal chemists to access a huge range of scientific information (binding, inhibition, structural features, classification, literature, patents and other kind of data) [8] . For example, the ZINC [9] , WOMBAT [10] , PubChem [11, 12] , BindingDB [13] , ChemEMBL [14] , DrugBank [15] databases, to mention only a few, allow webbased open-access to enormous volumes of data linking chemistry, biology, and medicine, and allowing small molecules to be considered in the context of a rich biomedical scenery.
In silico techniques also support the identification of drug-like chemical structures by applying simple rules to determine desirable pharmacokinetic and toxicity parameters. An estimated 68.7% of compounds in the Available Chemical Directory (ACD) Screening Database (2.4 million compounds) and 55% of compounds in ACD (240000 compounds) conform to Lipinski's "rule-of-five" (MW < 500, ClogP < 5, hydrogen bond donor atoms < 5, hydrogen bond acceptor atoms <5, and rotatable bonds < 10) [16, 17] . Since lead optimization quite often produces more lipophilic and structurally complex compounds, the simpler "rule-of-four" (MW < 400, ClogP < 4, hydrogen bond donor atoms < 5, hydrogen bond acceptor atoms < 8) was recommended for the design of screening libraries by Oprea et al. [18, 19] . A "rule-of-three" has been proposed by Congreve and coworkers [20] to favour molecular entities, or more correctly fragments, with MW < 300 g/mol, hydrogen bond donors < 3 and ClogP < 3 (see below). Ligand libraries which follow this rule are particularly useful for fragment-based drug design. They allow two or more non-overlapping ligand hits to be selected and linked together to create a more potent binder which still follows Lipinski's rule. In silico techniques also help to remove compounds with undesirable physicochemical properties by avoiding functional groups which are known to be reactive or which create false positives through indiscriminate binding. The potential of computer-based virtual screening (CBVS) has already been well demonstrated by the identification of several inhibitors and antagonists [21] . For example, screening of commercially available compounds with the crystal structure of dihydroorotate dehydrogenase (DHODH) resulted in the identification of novel cyclic aliphatic carboxylic acids that led to the discovery of SC12267 [22] as a patented drug candidate for rheumatoid arthritis. This compound is currently in Phase II clinical trials.
Structure-Based In Silico TRROV
Structure-based drug design (SBDD) is one computational methodology that has been quickly recognized and globally accepted by medicinal scientists. Moreover, the recent advances in system biology and drug affinity response have matured to help with the identification of potential targets. Complete genome sequences, together with the increasing number of structures obtained by X-ray crystallography or NMR have provided many new potential biological targets [23] . For example, the identification of inhibitors targeting HIV-1, approved by the FDA and therefore effectively on the market [24] , is one example of a major success of SBDD.
Homology Modelling
If no experimentally determined target structure is available, ab initio or comparative modelling techniques may be used to predict and model 3D structures. Whenever a sufficient sequence similarity (typically > 40%) is found, theoretical models of target structures may be built by homology modeling (also called comparative modelling) based on the general observation that proteins with similar sequences have similar structures, which might in turn allow the replication of an experimentally solved template structure into the trace of a query sequence [25] . This rule does not always hold. Even though higher sequence identity should lead to a better model, for some protein families which have only a few templates available (e.g. G-Protein Coupled Receptors, GPCRs), low similarity templates (<30%) might need to be used provided they have the correct overall fold. In any case, if higher identity is detected among the structural conserved regions, or at least if the function and physiological role is retained, structural similarity can be exploited for modeling purposes. Homology modeling programs such as Discovery Studio (Accelrys) [26] , Prime Module (Schrodinger) [27] , Advanced Protein Modeling (Tripos) [28] , and MODELLER [29] , to mention a few, are distributed by commercial vendors or academic institutions, and are widely used. Once homology models have been built from a given sequence alignment, additional steps of validation are mandatory to confirm the stereochemical quality of the predicted structures through backbone conformational angles analysis (i.e., a Ramachandran plot [30] ) or further refinement using molecular dynamics simulations since the errors from the homology model might be coupled with errors in other computational methods (docking, database search, etc.) which might lower the reliability of virtual screening hits. Several studies have confirmed that homology-built models can be an invaluable tool for SAR data interpretation. For example, homology modeling techniques have been used successfully to help find binders of the CB2 [31, 32] , A 2A [33] , A 3A [34] and 1 receptors [35] , renin peptide inhibitors [36] , selective anti-malarial agents [37] , benzotriazine compounds, acting on Src-kinase and endowed with better pharmacokinetic properties [38] , potent and selective ligands for protein kinase C theta [39] , and nicotinic receptor agonists [40] .
Binding Site/Binding Mode Analysis
Knowledge of protein structures enables SBDD to incorporate more detailed information about regions that are not accessible to the ligand. Identifying the binding or active sites in the target structure, often through the use of exclusion volumes or inclusion regions is of high importance. Generally, the initial steps comprise a surface analysis to identify or evaluate binding pockets or occluded clefts, and to characterize the active site's shape and its surrounding residues. These analyses play an important role for a variety of applications such as automated ligand docking, and further insights into the binders mechanisms might be gained according to similarity of related proteins clustering structurally related binding sites by shape and burial index. Some pocket detection algorithms implemented in computational programs such as Ligsite [41] , Qsite finder [42] , CAST [43] , PocketPicker [44] , and PASS [45] use geometric criteria to find clefts and surface depressions and hence to identify binding site residues. Because some conformational changes might occur, identifying the binding site residues accurately can be difficult. Hence, more reliable active site predictions can be carried out with others software resources for SBDD. To accomplish this task GRID [46] probes the site with small molecules or functional groups and calculates the enthalpy of the interaction between the probe and the protein atoms at points on a grid lattice to generate a molecular interaction field (MIF). These fields can then be contoured by energy to find the most favourable regions for an acceptor or a donor. Given the relationship between pharmacophores and molecular interactions, it is intuitive that MIFs can be used as an alternative to rule-based definitions. One of the most popular methods for calculating these fields is the GRID program.
Docking-Based VS
As long as knowledge of the protein active site is available, the interaction or fit between a binder and its protein target needs to be investigated. The prediction of the ligand conformation and its orientation with respect to the target structure is carried out using molecular docking [47] , where the ligand is placed inside the receptor in different orientations. Several approaches such as genetic algorithms, Monte Carlo, evolutionary algorithms, simulated annealing, empirical approaches, knowledge-based algorithms, and the Fast Fourier Transform are used to search and score the parameter space. For each pose, an energy-based score is calculated as a mathematical estimate of the protein-ligand interaction energy. This helps to investigate the interactions between the small molecule and the biological target, thereby providing context about biological activity.
Although the concept of docking seems to be simple, it adds complexity at several levels. For instance, adding flexibility to some regions of the protein can help in identifying new hits with better interaction very quickly, compared to docking a ligand with a rigid receptor. But, this requires more complex calculations because the protein of high con-formational energy score would result in idealistic positioning of the ligand. Some common programs are AutoDock [48] , Gold [49] , Glide [50] , DOCK [51] , ICM-Docking [52] , and FlexX [53] .
Nevertheless, pose prediction and ranking can be dramatically affected by the quality of the scoring function. Ignoring or mis-estimating the entropic contribution to binding, as well as other essential information (i.e. water molecules, hydrogen atoms positions, alternative side chains conformation, ligand induced fit or protein flexibility) are common problems. Therefore SBDD studies might give poor or misleading results. A possible way to lower the uncertainty of docking poses has been proposed by Al-Sha'er et al. [54] in which a docking-based comparative intramolecular contact analysis (dbCICA) is carried out to assess different docking settings capable to discriminate high and lowaffinity ligands according to selective hot spots located near amino acid residues of a binding cleft.
Indeed, the recently created Iridium data set might represents a promising development towards better SBDD methods. Protein-ligand structure data, historically used in docking methods, have been analyzed and pruned according to strict clerical filters and issues (i.e. element type, stereochemistry, bond order, R-factor, etc.), providing a solid platform for the development and validation on newer docking algorithms based on data with high levels of accuracy, quality and experimental consistency.
3D Pharmacophore Receptor-Based VS
According to IUPAC, a pharmacophore may be defined as "the ensemble of steric and electronic features that is necessary to ensure the optimal supramolecular interactions with a specific biological target structure and to trigger (or to block) its biological response". To a large extent, a pharmacophore is a non-atomic molecular model that a medicinal chemist would use for the identification and subsequent optimization of new molecules or potential leads.
Given the 3D structure of a target, either in the native form or in complex with affine ligands, the most frequent and straightforward practice is the extraction of critical "hot spots" from the active site in order to generate a snapshot of the specific interactions occurring in the binding process. In this context, GRID fields furnish valuable information on the type and the strength of interaction occurring on the protein's surface, without taking into account any effects derived from the ligand features. For instance a shape-based description of the binding site based on a GRID analysis originated fourpoint pharmacophore fingerprints, combined afterwards with a set of ligand pharmacophore fingerprints in the structurebased virtual screenings carried out with the FLAP program [55, 56] . FLAP is based on GRID MIFs in a two-step procedure. Firstly, the MIFs are condensed into discrete points representing the most favourable interactions, and all corresponding quadruplets of these points are used to generate different superpositions of a test molecule onto a template molecule. The superpositions are then scored in terms of their MIF field similarity [57, 58] .
On the other hand, a slightly different approach is applied in LigandScout [59] . A three-step analysis is carried out first, considering the ligand hybridization state and bond characteristics according to an extended heuristic approach together with template-based numerical analysis. Then, protein-ligand interactions (i.e. hydrogen bonds formation, electrostatic interactions, and hydrophobic contact) are taken into account in the development of a feature-based pharmacophore. Lastly, binding data are considered to support the formulated hypothesis, or at least one common feature pharmacophore is gained by the combination of several models. Similarly, the Tripos Inc UNITY program [60] applies the same type of philosophy in the generation of the pharmacophore hypothesis, but the 3D queries are enriched by the inclusion of nonchemical additional features such as lines, planes, centroids, and extension points defining the relationships between features in more geometrical terms. In the MOE software [61] , a higher level of control in the 3D-pharmacophore database search is provided by a consensus query from diverse set of aligned molecules, and also by the possibilities of considering both partial and systematic matching or even flexible matching rules.
Nevertheless, despite the valuable knowledge provided by the protein active site, a pharmacophore hypothesis always needs careful evaluation because of some inevitable pitfalls. For example, too many (> 7) chemical features can be identified without a proper ranking, passing therefore a too complicated query into a 3D database screening, and models based on a single macromolecule-ligand complex or a single macromolecule are not sufficient to reflect the whole set of QSAR.
Structure-Based De Novo Design
De novo design programs use linkers or chemical spacers (such as atoms, chains, or ring moieties) to merge the disconnected features of the pharmacophore to assemble a novel chemical entity. The positioning of fragments can be either pre-docked with the structure target or placed by the program. Receptor-based design can be carried out by two means: linking and growing techniques. In the linking process different small fragments such as amines, single rings, and hydrocarbons from the libraries are added simultaneously to different active site residues of the target [62] . Thus, the small fragments positioned at the binding site link to each other and form a final single compound. Fragment placing can be carried out via two different approaches, namely "outside-in" (i.e. fragment initially placed at the edges of the binding site) or "inside-out" (i.e. fragments are randomly attached to the binding site and built outwards). Software programs such as CAVEAT [63] , SPROUT [64] , NEWLEAD [65] , LUDI [66] , and BUILDER [67] can be useful to fulfil this requirement.
A somewhat different protocol is applied by AL-LEGROW [68] , where new compounds are generated from a randomly selected root atom "growth point" by adding atoms or small fragments. Next, small fragments are randomly selected from a building block list and added to the root, and the resulting fit to the binding site is evaluated. If the fit is acceptable, the new atoms are accepted, and the process is repeated up to a user-defined threshold. The program stops when the number of requested molecules has been generated. However, a weakness of this approach is the need of knowledge of 3D structures of the macromolecular targets by all the mentioned programs. Moreover, the sterically forbidden region of a binding site is not properly taken into account and, most and foremost, the compounds on-screen created might be difficult to chemically synthesize.
Ligand-Based In Silico Tools
It is much easier to crystallize small molecules than proteins, as indicated by the almost 20:1 ratio between the number of solved organic and biological crystal structures. Indeed, it might be estimated that given 100 newly identified biological targets (receptors, enzymes, nucleic acids, etc), only 10 would result in a valuable electron density map after the cloning, expression, crystallization, and diffraction. Given this relative paucity of 3D data for receptors, in silico ligand-based (LB) approaches remain to a large extent the most widely used approach in computational drug discovery.
In a valuable literature survey carried out on the main scientific journals over the last years, Ripphausen et al. [69] reported that applications based on LBVS) methods are on average more potent with respect to (SBVS) ones, which are nevertheless currently three times more popular. A plausible justification for the better performance of LBVS over SBVS might be ascribed to the lower level of complexity required by the first approach. Some of the major approaches of ligand-based in silico studies are described below.
2D Ligand Similarity Searches
The axiom that "similar molecules give similar activities" is not always true when applied to data prediction [70, 71] . However, 2D similarity methods perform well at leadhopping when applied to a diverse database, as measured by the enrichment factor, a cut-off fraction of a database indicating how many more actives are present than would be expected by a random scattering of actives in that database.
Topological ligand-based screening methods using databases of pre-computed descriptors often use only the connection table of the target molecule, without requiring 3D coordinates. Among them TOPOSIM [72] , DAYLIGHT [73] , UNITY [28] , DRAGON [74] , MACCS [75] , and other popular molecular fingerprint approaches use long bit strings to encode 1D or 2D projections of molecular topology or macroscopic properties such as solubility, pK a , logP, and toxicity. Despite their ease of use, a major caveat concerning 2D similarity searches rely on different molecular descriptors encoding different aspects of molecular structures, ranking therefore differently a given set of molecules in VS. It might be wise to combine multiple descriptors by means of Principal Component Analysis (PCA) or other discriminant analysis in prospective VS [76] .
3D ligand-Based Pharmacophore Screening
The possibility of simplifying a molecular entity encoding chemical function character into pharmacophore key elements has turned out to be the most effective type of pharmacophore model and greatly speeds up 3D database search [77, 78] . In this search queries are sketched from a "model" or "hypothesis" generated grouping atoms into features (i.e. acceptors and donors of polar bonds, non polar moieties, ionic spots) mimicking the chemical of more than one structural scaffold related to Euclidean pharmacophoric constraints as long as multiple ligands are taken into account. Building a good pharmacophoric hypothesis which can take into account conformational sampling and chemical feature alignment, is one of the key challenges in ligand-based pharmacophore modelling [79] .
To deal with flexibility, molecular conformations might be either pre-computed, requiring huge mass storage capacity, or generated on the fly, requiring more CPU time. It has been demonstrated that the pre-enumerating methods outperform the on-the-fly calculation approach [80] . Polling restraints [81] , systematic torsional grids [82] , directed tweak [83] , genetic algorithms [84] , and Monte Carlo [85] are the searching algorithms implemented in commercial some software packages like GALAHAD [86] , GASP [87] , PHASE [88] , and DISCO [89] . On the other hand, alignment is a less complicated but perhaps more critical concern. It is carried out according to different approaches generating a least-squares fitting of predefined anchor points or using Gaussian functions encoding a molecular property.
In this context, the methodology implemented by Greene et al. in CATALYST [90] is widely employed in more than one ligand-based assay. After a features representation step, encoding ligand-protein intermolecular interactions corresponding to different chemical clichés represented by one or more points, two to three-point configurations are compared to selected molecules of a reference dataset are identified and those that pass certain distance thresholds are then superposed by least-squares fitting. Although this style has been accepted as a standard algorithm, any pharmacophore elucidation achieved by CATALYST is still influenced by the user's parameters.
Very recently Cross et al. [91] presented a novel approach based on MIFs providing a common reference framework to compare both small (ligands) and macro (targets) molecules. FLAPpharm first aligns the structures and subsequently extracts the common interacting features in terms of their molecular interaction fields, pseudo-fields, and atomic points, representing the common pharmacophore as a more comprehensive pharmacophoric pseudo-molecule. The method might be also able to explain alternative binding modes.
Regardless of the accuracy applied in the conformational sampling and alignment steps, pharmacophore elucidation is not so trivial, and therefore the validation of the formulated hypothesis, typically not unique, is necessary. To fulfil this requirement modelers are used to properly select the ligands, afterwards split into the test and prediction sets. Moreover, suboptimal results might results from additional pitfalls: the possibility of multiple binding modes and the selection of the right template. Similar molecules do not always share identical pharmacological profiles. The threshold between agonism, antagonism, and allosteric modulation is somehow very tight, that is a single template might not be always the same to align each molecule across the data set.
Bearing in mind the above limitation, the pharmacophore approach cannot be deemed as a panacea for new drug discovery and development since the expectations are quite always overcome by the associated high costs in terms of time and accuracy of the results. Once a pharmacophore is elucidated, scaffold or lead hopping is afterwards performed with rules (conformation, computations, feature assignment, and fitting) similar to the ones of hypothesis generation, applied in this instance to larger (several millions) libraries of existing and commercially available compounds, with the main advantage to identify compounds exhibiting properties outside the ones used for building the pharmacophore. The same approach is always used in fragment-based drug design for the identification of potent fragments for further optimization (see below).
Shape Matching
Shape-matching approaches are based on the superposition and comparison of the 3D shapes of a set of molecules against a known active molecule. Compounds that have a shape similar to that of a well-known active will have a good probability of fitting in the biological receptor and may potentially have greater activity. The biggest problem with shape-matching techniques is the selection of the initial query conformation.
Often, the crystallographic conformation of the complexed ligand is used as the query. However, if there is no crystallographic information available for a target, computational methods have to be used. Usually, the lowest energy computed conformation is used in these cases, or different query conformations are calculated and the one most similar to superposed compounds is used in each case. Another limitation of shape-matching approaches is that if a target has an active site that can fit ligands in different ways, the query selected will represent only a single binding mode. Therefore, only those compounds in the database with this single shape will superpose correctly onto the query. Hence, other potentially active compounds may be missed. Perez-Nueno et al. [92] [93] [94] [95] proposed a spherical harmonic (SH) consensus shape-matching algorithm to help solve this problem. In this approach, the shape of a consensus (or average) pseudomolecule is calculated from the SH representation of each active. Hence, consensus shape can capture the essential features of several known high-affinity ligands and encode these in the form of a single representative pseudo-molecule.
3D-QSAR
3D-QSAR is a useful approach that can be interpreted as a pseudo-receptor or as a more refined pharmacophore query. In particular, a larger region of the bioactive space (four or five order of magnitude in term of K i , K d , EC 50 , IC 50 , etc) can be exploited incorporating low active molecules. In addition alignments can be proved on statistical validation criteria, and ultimately reformulated by a mere visualization and investigation of the outputs even if the subtle effects associated with inactive molecules may serve to add more noise than signal.
Since its first appearance, 3D-QSAR has essentially been intended as comparative molecular field analysis (CoMFA) [96] where the enthalpic and structural contributions are measured by sharp Lennard-Jones (steric) and softer Coulomb (electrostatic) potentials of a limited type of atom probes on a rectangular grid surrounding molecules aligned to match a pharmacophore on the assumption that the entropic contributions to the binding free energy will be similar for ligands having similar probe potentials. An increase or decrease in activity is further related to certain locations or potentials through partial least squares regression models, as done in CoMFA. However, errors in scaling, alignment, and interpretation can be introduced [125] . In order to overcome such problems, the comparative molecular similarity indices approach (CoMSIA) [97] was developed. Current CoMSIA models are less sensitive to alignment variations and use other (hydrogen bond donor, hydrogen bond acceptor, and hydrophobic) rather than classical fields which model better the entropic aspects of binding [98, 99] .
A significant improvement in this direction is provided by GRID potentials. Besides the advantages of modelling the pseudo-receptor environment through a large panel of molecular interaction fields (MIFs) most strictly resembling the enthalpic and entropic contributions to the binding process, alignment problems are surmounted replacing the ensemble produced by least square fitting with a vector representation of the 3D space. The large dimensions (>1000) of MIFs often hinder the most relevant grid points better depicting the receptor but recently an automated method for extracting hot spots from a field has been developed [100] .
Ligand-Based De Novo Design
The hits identified from HTS screens of large corporate compound collections, especially those of combinatorial chemistry origin, tend to be large albeit potent. The chemical optimization of those compounds has led to some high profile failures of lead series. These have been attributed to the reduced productivity of pharmaceutical industry [101] . Partially motivated by searching for an answer to this question, Lipinski's rule-of-five was proposed that have highlighted some important properties that good lead compounds should possess [16] . One of the factors identified is the correlation of high MW with poor solubility.
If one starts with very potent but high molecular weight lead compounds, optimization may result in molecules with even higher molecular weight with reduced solubility and this is generally associated with poor pharmacokinetic (PK) properties. To address this problem, a fragment-based drug design (FBDD) approach was proposed [102] . In the past fifteen years, FBDD has become an established strategy to discover novel chemical entities in both industry and academia [103] . The FBDD approach represents a rapid, resourceefficient, and productive route to the identification of novel hits in the early phase of drug discovery process. The first advantage is that the chemical diversity space is better covered with FBDD. In FBDD, smaller fragment libraries are required to probe chemical space more effectively while generating the same amount of information as generated by screening a huge number of compounds. The second advantage is that screening a fragment library achieves higher hit rates as compared to conventional HTS. This may be attributed to the fact that a fragment molecule can bind to various sub-sites of a target in many ways. Large molecules, on the other hand, contain more functional groups that may present more steric hindrance or electrostatic clashes than the fragment molecule in a binding site. These molecular incompatibilities prevent most large molecules from being accommodated in the protein pockets [104, 105] . Finally, the third advantage is that compounds optimized from fragments exhibit high binding efficiency per atom as compared to compounds optimized from HTS. FBDD has now evolved into a very successful drug discovery strategy since its conception in 1996 [102] . There is already an FDA approved drug [106] and at least 10 more compounds in clinical trials which originate from fragment screening and optimization approaches [107] . In recent years, FBDD has gained an important place as a screening tool for novel inhibitors. This is reflected in the number of publications on FBDD each year. In the year 2011 alone, over 125 papers (of which 17 are reviews) were published. Furthermore in the last decade at least 5 books were published dealing with methods and successes in FBDD [108] [109] [110] [111] [112] .
Computational screening also plays an important role in FBDD and a number of computational tools have been developed or adapted to be applied during different phases of FBDD. These computational methods are most useful when they are used in combination with experimental approaches. Similar to the conventional in vitro FBDD, there are three basic steps during in silico fragment based screening. Initially, a fragment library is designed which is then screened by a secondary virtual approach, generally molecular docking. In the final step prioritized fragments are optimized using computational methods for growing, linking, or both. Despite the many advantages in computational fragment based screening, there are some drawbacks as well. One of the most serious is the relatively low accuracy of predictions and another is the rapid accumulation of errors. Generally speaking, computational FBDD methods have lower accuracy than experimental FBDD approaches.
Combining Ligand-Based and Structure-Based Methodologies
As well as de novo design, another way to combine receptor and ligand information is the direct guided docking approach of Fradera and Mestres [113] , which introduces receptor-binding mode in-formation in docking extracted from complexes co-crystallized with other ligands. It is assumed that the binding mode is normally conserved between different ligands, although this is not always the case. Another approach is the construction of pharmacophore models considering both the characteristics of active ligands and the structure of the active site of the receptor, especially if cocrystallized ligand-protein complexes are available. The pharmacophoric features extracted from the alignment of known active ligands are combined with those extracted from the generation of a map of interactions of the active site of the receptor (hydrogen bond donors, hydrogen bond acceptors, and hydrophobic regions). Related to this, 3D-QSAR models can also use a combination of the ligand and receptor information.
A crucial element in the construction of 3D-QSAR models is the structural alignment of the ligands, which can be especially challenging when dealing with structurally diverse or highly flexible compounds. Hence, the utilization of alignment techniques based on binding site geometries and minimizations within binding sites can be an effective alternative to conformational searches and superpositions solely based on the molecular properties of the ligands. Another type of approach is based on encoding the 3D protein-ligand contacts in bit string "fingerprints" derived from the number of residues or atoms in the binding cavity of the protein. Each bit denotes the presence (1) or absence (0) of a particular interaction: hydrogen bond, hydrophobic contact, or van der Waals. The implementation of these "interaction fingerprints" can vary depending on the definition of the bit string and the type of interactions considered. The interactions of a ligand co-crystallized with a receptor are translated to an interaction fingerprint, which is used as a reference for the comparison with the interaction fingerprints extracted from the best configurations obtained by the docking of all the molecules of the database to screen. Receptor-based 3D-QSAR, in which receptor-ligand complexes are not used to directly calculate binding interactions, but only to generate the 3D alignment of the ligands, has been applied successfully to GPCRs, by means of docking studies conducted at homology models derived using rhodopsin as a structural template [114] [115] [116] [117] [118] .
3D Pharmacophore Receptor-Based + Ligand-Based
As previously reported, GRID-derived structure-based pharmacophores are one class of pharmacophore approaches that in our opinion provide a more realistic description of molecular interactions than simple point-based feature models. At first glance, the method may appear directly comparable with docking approaches, although in reality the information obtained is different. Structure-based pharmacophores describe potential interactions, and pose prediction with ranking is one application of this. Docking is solely designed for pose prediction and estimates the binding energy. For many applications, the methods are complementary, with pharmacophore approaches being followed by docking in a virtual screening cascade, or docking being used to predict binding poses from which a structure-based pharmacophore can be elucidated. Whichever method or combination is used to predict the binding pose or score the ligand, the gridderived structure-based pharmacophores clearly illustrate regions where ligands can be modified to design improvements, and the fields behind the pharmacophores may be used directly with chemometric methods to quantify the design using 3D-QSAR.
MULTI-TARGET VIRTUAL SCREENING
The multi-target is a novel and emerging drug discovery paradigm based on the idea that superior therapeutic efficacy and safety can be achieved by designing individual new chemical entities that can simultaneously target different points of a given pathogenic cascade. The enhanced efficacy of multi-target drugs could also stem from preventing the development of unwanted compensatory mechanisms, which might result in cellular redundancy. In fact, redundant mechanisms can activate alternative pathways, thus impairing the drug efficacy achieved by modulating a single protein activity. This is the major reason for using drug combinations in several different therapeutic areas. In this respect, multi-target drugs provide a valuable alternative to cumbersome and possibly risky drug cocktails [119] .
Once a suitable combination of targets has been identified and validated, a rational drug design project can begin by identifying multi-target hits. In a single-target endeavor, high throughput screening would represent a straightforward strategy for identifying initial hits. Although powerful, HTS is costly in terms of resources, time, and personnel, and the costs increase if multiple targets are to be considered simultaneously. Hence, as aforementioned, VS represents a fast and efficient alternative to HTS. We have shown in the previous sections how VS can be used to process large libraries of compounds in single-target screening studies. However, VS can be also straight-forwardly applied to the multi-target framework by applying the screening protocol to each target independently. The direct result coming from this kind of multi-target VS study is the identification of hybrid molecules that could be able to bind simultaneously to the selected targets. After, it is necessary to combine and analyze the generated results to decide which molecules to prioritize for testing. Following the principle of polypharmacology, a weaker activity could be preferable, if it involves multiple targets, compared to an activity that is potent but limited to a single protein. An experimental multi-target profile is likely to emerge from molecules that, even if they do not reach the top-ranking fraction in any single run, score on average adequately well and never drop below a given threshold. Some examples of a practical application of multi-target VS are the work of Wei et al. [120] , and Ma et al. [121] . Wei et al. successfully identified novel anti-inflammatory candidates displaying activity against phospholipase A2 and human leukotriene A4 hydrolase. First, they devised a common pharmacophore that combined relevant features from both targets. Then, they carried out independent structure-based VS runs, filtering out all conformations that did not match the common pharmacophore. The authors point out that none of the compounds eventually reported to be active would have been identified by simply testing top-ranking molecules. Ma et al. demonstrated that, at least for structurally related targets such as kinases, it is possible to train multiple support vector machines (SVMs) using only single-target inhibitors and to identify dual inhibitors by combining common hits.
FRAGMENT-BASED MULTI-TARGET DESIGN
FBDD has emerged as an effective alternative to high throughput screening for the identification of lead compounds in drug discovery in the past fifteen years. Fragment based screening and optimization methods have achieved credible success in many drug discovery projects with one approved drug and many more compounds in clinical trials. As mentioned above, FBDD starts with the identification of fragments or low molecular weight compounds that generally bind with weak affinity to the target of interest. The fragments that form high quality interactions are then optimized to lead compounds with high affinity and selectivity [122] . Moreover, the search for "magic shotguns" is slowly gaining a wider following, and so too are fragment-based approaches which, by design, are more likely to unveil multitarget hits than conventional approaches [123] . In fragmentbased multi-target design, the goal is to screen fragments against a panel of targets in order to find areas of overlap, to identify binding scaffolds capable of modulating the activity of two or more biomolecules simultaneously. One advantage of using fragments instead of screening molecules against a panel of targets is the reduction of the available chemical space to search. However, it is still challenging to pinpoint hits within a crowd of possible candidates. Hence, one crucial element is the design of fragment screening libraries. The chemical space of the library must be diversified to ensure the presence of different chemotypes. Nevertheless, before compiling the library, it is also convenient to extract information about target preferences from in-house data or from publicly available databases in order to enrich the library with scaffolds containing fragments that are found to be well accepted by the targets of interest [124] .
POLYPHARMACOLOGY COMPUTATIONAL TOOLS
Drug promiscuity may be defined as the specific binding of a drug-like molecule to more than one target. On the other hand, if a protein binds different ligands, it can be considered as a promiscuous receptor [125] . These notions are illustrated in Fig. 4 . The concept of "target-hopping", whereby a binder for one target can be considered as the basis for leads for another target has historically been extremely fruitful in lead discovery [126] . Another definition of promiscuity relates to the non-specific inhibition of a group of targets [127] . In terms of the binding of a drug to more than one target, polypharmacology can lead to multiple outcomes, both beneficial and harmful (i.e., therapeutic polypharmacology and adverse polypharmacology). Therapeutic polypharmacology includes the concept of treating multigenic, complex diseases by targeting multiple targets with one or more drugs, in order to effectively reset the regulatory network processes that are altered in the disease state. Adverse polypharmacology comprises the scenarios in which the "offtarget" binding of drugs leads to adverse effects. Such interactions include binding to protein targets other than the therapeutic target and binding to the therapeutic target in non-target tissue.
Nowadays, polypharmacology is becoming an increasingly important aspect in drug design. In the last 4 years, more than 30 drugs have been tested against more than 40 novel secondary targets based on promiscuity predictions [128] . Pharmaceutical companies are discovering more and more cases in which multiple drugs bind to a given target (promiscuous targets) and in which a given drug binds to more than one target (promiscuous ligands). Both of these phenomena are clearly of great importance when considering drug side-effects. For example, a common reason for terminating a drug development program is that the leads are found to be non-selective or promiscuous [129] . Thus, the in silico prediction of unwanted side effects caused by the promiscuous behaviour of drugs and their targets is highly relevant to the pharmaceutical industry. Considerable effort is now being put into the computational [130, 131] and experimental [132, 133] screening of several suspected off-target proteins in the hope that side effects might be identified early, before the cost associated with developing a drug candidate rises steeply [134] . On the other hand, promiscuity is not always unwelcome and it can even be exploited for drug development. The use of old drugs for new targets has been shown to provide a promising way to reduce both the time and cost of drug development [135] .
Given that it is currently infeasible to screen a drug against all of the proteins expressed by the human genome, several computational techniques have been developed to predict the pharmacological profiles of known drugs [137, 138] . These range from the well-known docking of compounds into protein structures to the use of network pharmacology and machine learning methods [139] [140] [141] , sequence comparison [142] , side-effect similarity [131, 143] or chemogenomic approaches such as fingerprint/pharmacophore comparison methods [144] . These in silico chemogenomic approaches typically aim to relate protein receptors to each other quantitatively based on their similarity in primary sequence space, ligand chemical [145] or pharmacophoric [145] descriptor space, ligand-receptor pharmacophoric descriptor space [145] , pharmacophoric binding pocket descriptor space [146] , and more recently in their ligand shape space [147] [148] [149] or binding-pocket shape space [150] . Also, recent techniques try to relate the complex drugprotein interaction profiles with effect profiles [143] , or to predict drug-target interactions based on complex network theory [151] . These approaches are summarized in Fig. 5 and are described in more detail in the following sections.
The first and most common technique for studying polypharmcology relationships use e.g. the BLAST [152, 153] or FASTA [154] sequence alignment tools to create similarity maps in protein sequence space [155] . Subsequently, machine-learning approaches are now commonly used to exploit their ability to recognize conserved molecular patterns in ligand-protein interactions and to classify compounds according to predicted target interactions.
Self-Organizing Maps
Self-organizing maps (SOMs) use a set of connected vectors of neurons to model the relationships amongst groups of objects by assigning similar input data points to related neurons. Thus, SOMs allow high-dimensional input data to be projected onto a lower dimension (often 2D), according to the form of the neuron network [156] . SOMs were initially used to design screening libraries and to perform scaffoldhopping. Now they have gained interest in drug re-purposing to find new off-targets for a given set of compounds. In this way, a set of molecules with known biological activity can be used to train a SOM, and a set of chemical compounds of interest can then be projected onto this map. The analysis is carried out following the supposition that the projected molecules assigned to the same neurons as the annotated training compounds will have related targets.
Bayesian Classifiers
Naive Bayesian classifiers are based on the assumption that every feature (i.e. for small molecules, normally a pharmacophore or a substructure) depends only on the class that it belongs to (bioactivity with respect to a certain target) and not on other features. Although this is not strictly true in most cases, naive Bayesian classifiers can be successful in practice. For example, Nidhi et al. used chemical descriptors [157] to train a model on 85% of the WOMBAT [158] compounds to predict the targets of the remaining 15% and the targets for several MDL Drug Data Report (MDDR) [159] activity classes. A similar approach has been used by Nigsch et al. [139] , Niijima et al. [140] , and Takigawa et al. [141] .
Linear Regression Models
Linear regression models are also applied to study drugtarget interactions, such as the work of Zhao et al. [160] , who developed a computational framework called drugCI-PHER, which is based on the observed correlation in pharmacological and genomic spaces. They propose three linear regression models that relate therapeutic similarity, chemical Fig. (4) . Drug Promiscuity. Left: multiple drugs bind to a given target (promiscuous target, such as the kinase p38 [233] . Right: a given drug binds to more than one target (promiscuous ligand, such as the hormone testosterone [136] similarity, and their combinations to the relevance of the targets based on a protein-protein interaction network.
Support Vector Machines (SVMs) and Substructural Analysis
SVMs as well as sub-structural analyses have also been used to study drug-target interactions. Jacob et al. [161] employed SVM and Van der Horst et al. [162, 163] employed sub-structural analysis to relate GPCRs via their ligands, and also to estimate how well ligand-target pairings could be predicted in cases where no ligands of a particular target are known. Van der Horst et al. found that in those cases, 93% of the targets ligands could be identified with above-random reliability even if no ligands were given in the training dataset, thereby illustrating that unknown ligand-target pairs could be predicted by computational models.
Yabuuchi et al. [164] developed the chemical genomicsbased virtual screening (CGBVS) approach, which has the potential to identify novel scaffold-hopping compounds and to assess their polypharmacology by using a machinelearning method to recognize conserved molecular patterns in comprehensive compound-protein interaction (CPI) data sets. The CGBVS strategy consists of five steps: CPI data collection, descriptor calculation, representation of interaction vectors, predictive model construction using training data sets, and predictions from test data. CGBVS incorporates multiple CPIs, numerically represented as vector descriptors, which integrates both chemical structures and protein sequence data. This appears to provide CGBVS with a relatively high ability to predict ligand binding to multiple proteins (a measure of selectivity), while allowing scaffold hopping through the use of CPIs. CGBVS predictions are based on extraction of conserved patterns from subdivided interaction vectors involving both proteins and their corresponding ligands. Yabuuchi et al. successfully identified novel, scaffold-hopping ligands by using CGBVS. Other computational approaches conceptually similar to CGBVS approach are Faulon et al. [165] , Jacob and Vert [166] , and Wassermann et al. [167] .
Network Pharmacology
Advances in systems biology are revealing a phenotypic robustness and a network structure which suggests that exquisitely selective compounds may exhibit lower than desired clinical efficacy compared to multi-target drugs. This new appreciation of the role of polypharmacology has sig- Fig. (5) . Polypharmacology computational tools. Diagram of the several existent polypharmacology computational approaches: chemogenomic approaches, machine-learning approaches, network pharmacology and drug-side effect prediction for in silico computational profiling and drug repositioning. The different approaches act on the polypharmacology (ligand-based, target-based, or target-ligand-based methods), systems pharmacology, and drug action levels. As a description for the binding of a drug to more than one target, polypharmacology can lead to multiple outcomes, both beneficial and harmful (therapeutic polypharmacology and adverse polypharmacology). Therapeutic polypharmacology includes the concept of treating multigenic, complex diseases by targeting multiple targets with one or more drugs, in order to effectively reset the regulatory network processes that are altered in the disease state. Adverse polypharmacology comprises the scenarios in which the "off-target" binding of drugs leads to adverse effects. Such interactions include binding to protein targets other than the therapeutic target and binding to the therapeutic target in non-target tissue. In a systems pharmacology view of drug action, a drug interacts with multiple primary and secondary targets. These targets exist within a complex network, which can mediate the response to the drugs leading to both therapeutic and adverse effects. Current polypharmacology approaches aim to predict drug-target binding, off-target binding and possible adverse effects.
nificant implications for tackling the two major sources of attrition in drug development: efficacy and toxicity. Integrating systems biology and polypharmacology holds the promise of expanding the current opportunity space for druggable targets. Furthermore, another promising area in networkbased prediction of drug targets is the ability to predict combinations of targets, or protein complexes, which will prove to be most efficacious and safe when targeted together. Since networks emphasize the relationships between proteins, they can suggest pairs or groups of drug targets that can work well together to treat a disease. The global understanding of diseases and drug effects based on network relationships between drug targets can also allow re-purposing of existing drugs with known targets for an individual use or use in combination therapies for different diseases. Such re-use of existing drugs has the advantage that their individual safety has already been established. Thus, combination therapy using previously approved drugs could lead to safer and more efficient treatments. However, the rational design of polypharmacology faces considerable challenges in the need for new methods to validate and predict synergistic effects of drug combinations and optimize multiple structure-activity relationships while maintaining drug-like properties. Advances in these areas are creating the foundation of the next paradigm in drug discovery: network pharmacology [168] [169] [170] .
Network pharmacology offers a way of thinking about drug discovery that simultaneously embraces efforts to improve clinical efficacy and understand side effects and toxicity, two of the most important reasons for failure. Several studies have shown the power of network analysis in understanding biological systems. As an example, Cheng et al. [140] developed three supervised inference methods based on complex network theory to predict drug-target interactions and used for drug repositioning, namely drug-based similarity inference (DBSI), target-based similarity inference (TBSI), and network-based inference (NBI). They created a drug-target network with NBI based on 12,483 FDAapproved and experimental drug-target binary links, and some new drug-target interactions were further predicted. Their results indicate that these methods could be powerful tools in prediction of drug-target interactions and drug repositioning.
Similarity Between Drug-Protein Interaction Profiles and Side-Effect Profiles
Many drugs exert their effects via multi-target interactions, as hypothesized by polypharmacology. While these multi-target interactions are responsible for the clinical effect profiles of drugs, it is not straight-forward to cover the complex relationships between them. Current methods try to relate complex drug-protein interaction profiles with effect profiles, such as the work of Simon et al. [140] whose statistical analyses confirmed a close relationship between the studied 177 major effect categories and interaction profiles of ca. 1200 FDA-approved small-molecule drugs.
Chemogenomic Approaches
Chemogenomics aims to systematically studying the biological effect of a multiple small molecular weight ligands on a wide array of macromolecular targets. Since the quantity of existing data (compounds, targets and assays) and of produced information (gene/protein expression levels and binding constants) are too large for manual manipulation, information technologies play a crucial role in analysing chemogenomic data [138] . Therefore, chemogenomics has been defined as the investigation of classes of compounds (libraries) against families of functionally related proteins. In this definition, chemogenomics deals with the systematic analysis of chemical-biological interactions. Thus, chemogenomics extends the principle that similar molecules are likely to have similar properties [171] .
These in silico chemogenomic approaches typically aim to relate protein receptors to each other quantitatively based on their similarity in primary sequence space, ligand chemical or pharmacophoric descriptor space, ligand-receptor pharmacophoric descriptor space, pharmacophoric binding pocket descriptor space, and more recently in their ligand shape space or binding-pocket shape space. The following sections explain in more detail these approaches.
Ligand Chemical Descriptor Space

2D and 3D Ligand Descriptors
Other groups have also explored both 2D and 3D descriptors with respect to their ability to predict protein targets of ligands where no similar structures exist in the training sets. For example, Nettles et al. [172, 173] used 2D fingerprint and 3D feature point pharmacophores (FEPOPS) molecular descriptors to predict protein targets for ligands. They show that more "abstract" 3D descriptors such as FEPOPS which consist of just four pharmacophoric points for each molecule are better than more "exact" 2D fingerprints in those cases where no similar ligand-target associations are known.
Also a hybrid 2D/3D target prediction called ReverseScreen3D has been published recently [174] . Firstly, 2D fingerprints are used to calculate the similarity of the query molecule to every ligand structure in the ligand-target interaction database, which has in turn been derived from clustering the Protein Data Bank (PDB). In an optional second step, the database ligand of each target cluster with the highest similarity to the query molecule is then used as a template for which 3D matching of the query is performed. Kinnings et al. performed a validation procedure for 20 compounds and experimental targets could be confirmed in the majority of cases [174] .
Protein-Ligand Fingerprints
Protein-ligand fingerprints have also been used as chemogenomics-driven predictive approaches to identify ligand-target pairs. For example, Weill et al. developed a novel low-dimensional protein-ligand fingerprint-based (PLFP) method [175] encoding both chemical and biological properties and which is suitable for exploring chemogenomics space. PLFP method captures the pharmacophore properties of ligands and their respective transmembrane binding cavities and was found to show preference for SVM classifiers, where it achieved nearly 90% precision in determining true from false pairs. Weill et al. show that protein-ligand fingerprints outperform the corresponding ligand fingerprints in mining the GPCR-ligand space. Because they can be applied to a much larger number of receptors than ligand-based fingerprints, protein-ligand fingerprints represent a novel and promising way to directly screen protein-ligand pairs in chemogenomic applications.
The Similarity Ensemble Approach (SEA) [176] is a target prediction method that is based on the distribution of features in each bioactivity class of molecules, and which employs a BLAST-derived algorithm to develop minimal spanning trees considering chemical similarity. SEA estimates target similarity, which is ranked based on their ligands' chemical similarity. Keiser et al. [177] relate receptors to each other according to the chemical similarity of their ligands. In SEA, the calculated probability that two molecules might interact with the same target by chance is expressed using an expectation value, which is conceptually similar to the E-value used in sequence alignment software such as BLAST [152] . The authors applied the SEA method to large scale study of more than 3000 FDA-approved drugs against hundreds targets and identified new cases of drugtarget interactions, some of them were validated in vitro to be potent with high affinities [152, 178] .
Topological Descriptors: PHRAG, FPD, SHED and RED Descriptors
Furthermore, topological descriptors based on molecular features have also been shown to be useful to relate proteins in ligand space. Novel sets of topological molecular descriptors have been recently reported, e.g. SHED (Shannon Entropy Descriptors) [179] and RED (Renyi Entropy Descriptors) [180] . SHED descriptors are calculated from distributions of atom-centered feature pairs extracted from the topology of molecules and their scores reflect the distribution of pharmacophore features in a molecular constitute. On the other hand, RED descriptors are based on generalized Renyi entropy as a variability measure for a feature-pair distribution in contrast to SHED descriptors. Greogori-Puigjané et al. [152] applied SHED descriptors to mine chemogenomics space of more than 700 drugs against 600 targets. Their results conclude that compounds targeting aminergic GPCRs exhibit the most promiscuous pharmacological profiles seen among drugs.
Mestres et al. relate proteins in ligand space using three in-house molecular descriptors (PHRAG, FPD, SHED) [181, 182] . In their work [183, 184] , they annotated a library of molecules targeting nuclear hormone receptors (NHRs). Using a hierarchical classification for 2000 ligands and 25 receptors, they recovered chemogenomic links bridging ligand to target space to distinguish selective from promiscuous scaffolds. Using SHED based on the distribution of atom-centred feature pairs, they are able to screen any compound collection to identify hits presenting SHED distances to a reference NHR ligand beyond a defined threshold and which are therefore likely to share the same NHR profile.
Ligand-Receptor Pharmacophoric Space
Pharmacophores have been widely used in many areas of computer-aided drug design but not commonly in target fishing applications. The idea to screen protein ligand-derived pharmacophores in order to identify potential targets of bioactive ligands was applied by Langer et al. in a series of retrospective screening experiments focusing on small protein ligand matrices [185] [186] [187] . Interactions between the ligand and the target are represented at an abstract level as pharmacophore features without an explicit requirement for a hit molecule to have certain atom connectivity. This property makes pharmacophores directly applicable for unearthing ligand-target links not obvious from atom connectivity alone. Pharmacophores can be generated by overlaying a set of ligands and identifying shared pharmacophore features. If a co-crystallized protein model exists, the key interactions between the ligand and the protein can be directly defined to derive a structure-based pharmacophore. Hence, the use of receptor ligand-derived pharmacophore searches as a way to link ligands to putative targets is becoming more common, although it has not yet become yet a standard in silico ligand profiling method given the absence of an exhaustive collection of protein ligand based or ligand-based pharmacophore databases, and the lack of clear benchmarks for comparing the approach to other commonly used computational profiling strategies (2D and 3D ligand similarity search, protein ligand docking). The work of Meslamani et al. [145] helps in this respect, Meslamani et al. developed PharmaDB, which is currently the largest collection of structure-based pharmacophore (68056 entries) from 8166 protein ligand Xray structures. They profiled a diverse set of 157 PDB [188] ligands using 10 screening protocols on the entire pharmacophore collection, and they compared pharmacophore mapping to another 3D structure-based method (docking) and to ligand-centric approaches (2D and 3D similarity search).
The first software module supporting the profiling of bioactivity spectra using a pharmacophore-based approach was Ligand Profiler, distributed with Discovery Studio [189, 190] . The program allows screening collections of compounds (single-or multi-conformational databases) against a series of pharmacophore models defined by the user. The ligand profiler maps each input ligand against all selected pharmacophore models. A fit value is computed that is a measurement of how well the compound maps the chemical function-based features of the pharmacophore and the results can be displayed as a heat map visualizing which compounds are likely to bind to which targets. Also a web interface has been published which employs pharmacophores to predict protein targets of small molecules, entitled PharmMapper [191] .
Binding Pocket Descriptor and Shape Space
With the increase in recent years of approaches for comparing protein pockets [192] such as four-point pharmacophoric descriptors (FLAP [55] ), three-point pharmacophoric descriptors (Cavbase [193] , SiteEngine [194] , SuMo [195] ), geometric hashing methods (Kinnings and Jackson [196] ), and graph-matching-base algorithms (IsoCleft [197] ), the notion of a binding pocket similarity space has also been proposed. This is based on the principal that protein binding pockets are the place where the interactions between a protein and a ligand are formed. Hence, they must have complementary shapes and physicochemical properties to the small molecules that they accommodate. Therefore, calculating the similarity of binding pockets allows proteins with similar function and selectivity for the same binding partners to be related. For example, Weskamp et al. compared targets by the similarity of their binding pockets using the LIGSITE program [198] . Milleti et al. related receptors to each other using pocket-based "shape context" descriptors [199, 200] . Perez-Nueno et al. [150] developed a shape-based approach that uses spherical harmonic (SH) representations [201, 202] to compare molecular surfaces efficiently. Their approach is based on the notion that since shape complementarity is an essential feature for molecular recognition, using ligand and binding pocket shapes should provide a good way to characterise their properties. If two binding pockets of different proteins share a common shape, it is likely that ligands that bind to part of one binding pocket will also be recognized in the corresponding part of the other pocket. On the other hand, if two ligands of different proteins share a similar shape, it is likely that both of them will complement the shape of each binding pocket. Hence, by identifying similar ligands and binding pocket shapes, their approach provides a shape-based way to predict promiscuous ligands and targets. They applied their approach to a wide range of ligands from the MDDR database, and for which crystallographic proteinligand complexes exist in the PDB and analyse the correlation between binding pocket and ligand shape spaces. They also compare their promiscuity predictions with experimental activity values extracted from the BindingDB database [203] .
Ligand Shape Space
More recently, methods using 3D molecular similarity have been developed, such as SHAFTS (SHApe-FeaTure Similarity) [147, 204] , ROCS (Rapid Overlay of Chemical Structures)-based target fishing [148] , and GES [149] in order to relate targets based on the shape of their ligands. Moreover GES is able to predict quantitatively the relationships between targets, by transforming the Gaussian similarity score into a probability value, or "p-value".
SHAFTS adopts hybrid similarity metric of molecular shape and colored (or labeled) chemistry groups annotated by pharmacophore features for 3D similarity calculation and ranking, which is designed to integrate the strength of both pharmacophore matching and volumetric similarity approaches. The feature triplet hashing method from PharmMapper Server is used for fast molecular alignment poses enumeration, and the optimal superposition between the target and the query molecules can be prioritized by calculating corresponding "hybrid similarities", which is a weighted summation of volume overlap and feature points fit value described by Gaussian density functions. SHAFTS is suitable for large-scale virtual screening with single or multiple compounds as the query "templates" regardless of whether corresponding experimentally determined conformations are available. The problem of molecular flexibility is addressed by means of a conformational ensemble generated either on-line or off-line, and only the top ranked conformer with the highest similarity score is regarded as the final result for the current target molecule.
AbdulHameed et al. [148] developed a ROCS-based target fishing approach to be used as a drug re-purposing tool. They first generated a chemogenomic database for linking individual protein targets with a specified set of drugs or target representatives. They generated target profiles for a given query molecule by computing the maximal shape/chemistry overlap between the query molecule and the drug sets assigned to each protein target. The overlap was computed using the 3D-similarity program ROCS [205] . Their method successfully identified off-targets for several drugs in agreement with known experimental data.
The Gaussian Ensemble Screening (GES) approach is a fast way to predict quantitatively the relationships between drug classes. In the GES approach [149] , a cluster of molecules with similar spherical harmonic surface shapes is represented as a Gaussian distribution with respect to a selected centre molecule. By calculating the Gaussian overlap between pairs of such clusters, the similarity between drug classes can be rapidly calculated analytically [150] . This provides a fast way of comparing target families without requiring thousands of bootstrap comparisons as in current promiscuity prediction approaches. Furthermore, the observed distribution of the GES cluster overlap scores is also found to follow a Gaussian distribution. Hence, each Gaussian similarity score can readily be transformed into a probability value, or "p-value", in order to quantify the relationship between drug classes. Perez-Nueno et al. present results obtained when using the GES approach to predict relationships between drug classes in a subset of the MDDR database. Their results indicate that GES is a useful way to study polypharmacology relationships, and a novel way to propose new targets for drug repositioning.
A characteristic of all these polypharmacoly tools is that they must be able to deal with large amounts of data with high computational speed and an intuitive representation of the results. Hence, it is not surprising that data-mining, machine-learning, and fast ligand shape-based techniques are starting to be more widely applied in this field. Generally, these approaches are tested on large biologically annotated compound libraries such as the publicly available DrugBank which summarizes the data on nearly 4600 approved drugs and experimental compounds in clinical studies [206] , ChemblDB which comprises more than 600000 distinct compounds with almost 3000000 measured biological activities [207] , the commercially available Wombat with 154236 entries over 307700 biological activities on 1320 unique targets [158] , and MDDR, a compilation of about 169000 druglike ligands in about 663 activity classes [159] , between others.
Moreover, some of the above approaches applied to these large biologically databases have a promiscuity search webserver such as ChemMapper (http://59.78.96.61:8080/ chemmapper/index.html) [147] , Drug repurposing Database (http://www.drugrepurposing.info/switch_index.php), DrugPredict (http://www.drugpredict.com/default/main), Promiscuous (http://bioinformatics.charite.de/promiscuous/), PDSP Ki database (http://pdsp.med.unc.edu/pdsp.php), NIMH/ SNIDD Tracer database initiative (http://pdsp.med.unc.edu/ snidd/), or the Binding DB Database (http://www.bindingdb. org/bind/chemsearch/marvin/BatchStructures.jsp) which can find all of the targets related to one chemical compound according to a threshold similarity criteria.
CASE STUDY: GPCR DRUG DESIGN
GPCRs are located at the cell surface and are responsible for the transduction of an endogenous signal into an intracellular response. GPCRs comprise a large protein super-family sharing a conserved structure of seven transmembrane (TM) helices. These helices surround a small molecule or peptide binding site within the TM domain, and are linked by three extracellular loops (ELs) and three intracellular loops (ILs). ELs vary significantly and generally play an important role in ligand recognition.
Until recently, bovine rhodopsin was the only GPCR structure solved by crystallography [208] . Knowledge of how drugs interact with GPCRs was therefore limited to models based on homology and site directed mutagenesis (SDM) experiments. However, in recent years, several new apo and holo GPCR structures have been solved, namely 1 and 2 adrenergic [209] [210] [211] , adenosinic A 2a [212,] , dopaminergic D 3 [213] , histaminergic H 1 [214] , chemokine CXCR4 [215] , opioid [216] , [217] [218], muscarinic M 2 [219] and M 3 [220] , and tachykinin NK 1 [221] receptors of different sources. These structures have provided further insights into the 3D topology of GPCRs, allowing more accurate GPCR models by comparative and homology building [222] and better virtual screening performance [223] . With this enlarged set of structural templates, high-throughput docking has become a more realistic opportunity for the study of agonist and antagonist-bound binding sites.
Although the GPCR signalling mechanism is not clearly understood, it is believed that when an endogenous agonist binds to the TM binding site, it causes conformational changes to be propagated through highly conserved "conformational switches" in the TM helices, leading to Gprotein signalling [224] . This implies that all GPCRs possess a common conformationally flexible TM region that allows them to move from an unbound or antagonist-bound state to an agonist bound signalling state. For the CXCR4 and CCR5 co-receptors, it is thought that chemokines activate the receptor at least in part via its N-terminal residues near the transmembrane region, and that CCR5 and CXCR4 antagonists allosterically prevent switching to the agonist-bound state [225, 226] .
In addition to the inevitable inaccuracies inherent in homology models, an additional complication when modelling GPCR structures by homology has been that until recently most likely all of the available structures are in the "unactivated" conformation. Bissantz et al. [227] proposed that homology models based on the unactivated state of rhodopsin could be suitable for structure-based VS of antagonists but not of agonists. On the other hand, Shim et al. [228] and Evers et al. [229, 230] have developed knowledge-based and pharmacophore-based approaches to predict activated agonist-bound forms of the receptor that could extract known agonists from a VS library. An important recent development has been the solution of the structure of opsin, the ligand-free form of rhodopsin [231] , which is found to be quite different from the known GPCR structures. The most prominent features of opsin are the activating movement of TM6, rearrangements in regions of TM5 and TM6, and restructuring of the helix 8 kink of TM7, which correspond to an active or partially active conformation. This suggests that future structure-based modelling exercises should use an activated or unactivated GPCR template for screening antagonists or agonist inhibitors, respectively [232] .
Moreover, it has been seen that GPCR inhibitors present significant polypharmacology. In their work on drug-target interaction networks, Mestres et al. analysed both drug properties and target families. From the analysis of drug properties, it was observed that small hydrophobic drugs appear to be significantly more promiscuous than large hydrophilic drugs, whereas from the analysis of target families, the drugtarget interaction network composed by drugs targeting GPCRs was found to be visually more dense and significantly more interconnected, with many targets collapsed in the centre of the network, than any of the networks derived for the other target families in their study. Both findings converge when realizing that small hydrophobic drugs are known to interact primarily with GPCRs, whereas the majority of the large hydrophilic drugs appear to be enzyme inhibitors. This is consistent with the fact that generally, GPCRs have large binding pockets which can accommodate ligands in different ways. Hence, it is common to find promiscuity due to differential ligand positioning inside the GPCR family from both the "multi-conformer binders" and "multisite binders" categories [233] .
The first promiscuity category (the more frequently explored one) arises when ligands bind in a variety of ways in a single pocket site. Such targets are said to have "multiconformer binders" [234] . This generally occurs with a series of diverse analogs of a given scaffold family, or when ligands with similar scaffolds bind to the same receptor pocket. It is also frequent when dealing with highly flexible ligands. For example, flexible ligands with rotatable fragments may adopt different conformations to bind a given binding pocket. The second category arises when a given target pocket has multiple interaction sub-sites. The ligands that bind these targets may be described as "multi-site binders" [235] . This is most frequently the case in targets with large binding pockets that might accommodate more than one ligand simultaneously (co-operativity mechanism [236] ). For example, different ligands with different scaffolds may rigidly bind to different sub-sites of a given binding pocket. Additionally, proteins can themselves also have multiple binding pockets. Depending on the target pocket, the corresponding ligands will activate or block a different biological function. In both cases, the positions of the protein backbone and side chains can be induced to change in response to ligand binding.
Promiscuity due to multi-conformer binders is seen in many computational protocols for structure-based drug design, and it can be taken into account when scoring affinity. For example, rigid body or semi-flexible docking protocols should use as input some 10 to 20 representative low-energy conformational structures of the ligand, each of which deviates from the minimal energy conformation by a relatively small amount (e.g. no more than 5 Kcal/mol). From those input conformations, only the structures that can be docked into the binding site without significant steric clashes are retained. The final docking score can then be taken as a weighted average of the binding energies of several docked conformers and may be used to estimate affinity. Accordingly, some docking approaches weight the final poses thermodynamically and include information about all poses in the affinity prediction [237] . Hence, these approaches can take into account the possibility that multiple binding modes contribute similarly to the overall affinity.
For example, for CXCR4 inhibitors, Wong et al. [226] and Pettersson et al. [238] have reported binding-mode analyses for bicyclam, monocyclam, and noncyclam compounds [239] . Both agree that none of the dockings into CXCR4 can explain all mutant results by a direct ligandreceptor interaction. That is to say, none of the predicted binding modes involved all of the residues known to affect the binding of the well-known CXCR4 bicyclam, monocyclam, or noncyclam inhibitors. In other words, it seems that different ligands bind in different ways within the SDMdefined pocket. Fig. 6 shows the 3D structure of the GPCR CXCR4 with three binding sub-sites in the SDM-defined binding pocket highlighted in colour. Furthermore, MD simulations are commonly used to refine docked-binding poses by allowing flexible motions of both receptor and ligand, and by taking into account solvation effects. CXCR4 antagonist binding modes refined by molecular dynamics have also been reported in the literature [238,240- However, the possible existence of multiple binding sites is often not explored in computational protocols. Given that some targets have multi-conformer binders or multiple pocket sub-sites, it is unrealistic to expect that a single VS query can select all possible active compounds in such cases. Pérez-Nueno et al. [233, 243] highlighted the importance of considering multiple sub-sites for targets that are known to have diverse ligand scaffolds, and they demonstrated the improvement in VS results that can be achieved when each sub-site is considered as an independent target pocket. In the same way, Taha et al. developed a method for exploring multiple binding modes using a ligand-based approach. Their method is based on an elaborate pharmacophore exploration followed by a QSAR-based selection of the optimal combi- nation of orthogonal pharmacophores that encode the corresponding binding modes [244, 245] .
GPCR Virtual Screening
Receptor-based In Silico Tools Applied to GPCR
The choice of a good balance between time and effort dedicated for the accuracy and quality of theoretical models fuels debate between researchers interested in GPCRs. In some instances (lead optimization) supplementary and timeconsuming assays (i.e., new mutants cell lines, additional affinity or efficacy data) might be required for receptor validation, while in others (lead identification) a more dépêche, but with lower enrichment, receptor model might be sufficient. Various receptor modelling, refinement, and docking protocols, aiming to virtual screening and new lead are found in the literature [246] [247] [248] [249] [250] [251] [252] [253] [254] [255] .
One of valuable examples is the NK1 receptor homology modelling using the MOBILE by Evers and Klebe on the high-resolution X-ray structure of rhodopsin [256] . A merit of this approach is essentially encoded in a diligent modelling of the binding pocket shaped by the explicit inclusions of ligand information. Briefly, in MOBILE ligands are first docked into crude homology models, further improved defining some restraints, in terms of the knowledge-based distance-dependent pair potentials compiled from crystallographically determined protein-ligand complexes. The same potentials are then used in the selection of the most favourable models according to the interactions between the ligands and the generated binding cleft. Subsequently, a pharmacophore model was deduced on the analysis of known NK1 antagonists interacting with the generated model, and guided a 2D and 3D database search with UNITY. This virtual screening has been further successfully applied for the identification of seven compounds, from which one showed affinity in the submicromolar range. The same type of approach led the discovery of antagonists of the 1a adrenergic receptor [257] . In a later study by Kneissl et al. [258] , automated procedures for the modelling were applied to the same NK1 receptor, exploring the impact of both bovine rhodopsin and the human 2 adrenergic structures as templates. This study was guided by the successful results of Nowak and co-workers with the 5-HT 1A receptor [259] improving the model building and validation process by docking a potent ligand into a set of many decoys models, generated employing MODEL-LER and sampling the conformational space, to identify those side chain conformations of the binding site that are advantageous for ligand binding according to the docking scores. A related workflow was used by Taha et al. with MCH-R1 [260] .
A slightly different method was presented by Cavasotto et al. [261] in a ligand-steered homology MCH-R1 model. In this study, several structural arrangements of the receptor cavity were clustered according to shape similarity, and the accuracy of the models validated by their ability to discriminate binders and non-binders in a virtual screening of known MCH-R1 antagonists seeded within a GPCR class A ligand library. This methodology appeared to be attractive when little structural information about ligand-protein interaction is available, because both ligand and receptor are considered flexible throughout the modelling process. A docking-based alignment, employing Jain's scoring function [262] and giving self-consistent CoMFA models, was also achieved by Abu-Habbad et al. [260] for a series of inhibitors acting on the same MCH-R1.
A particular instance is reported by Kellenberger et al. [263] in the first discovery of non-peptide modulators of the chemokine receptors identifying unknown agonists while searching for antagonists of the CCR5 receptor. These surprising results suggested a certain degree of similarity, as recently demonstrated for bovine rhodopsin and 1 , between the activated and inactivated states of TM structure not only in chemokines receptors but probably also for others GPCRs.
In all the above examples databases screenings and new leads identification were driven by theoretical, and not experimental, receptor scaffolds. Nonetheless, a rather interesting result was achieved by Carlsson et al. [264] in the development of novel dopaminergic agents. In this study, the authors carried a docking screen against the homology model built on the 2 adrenergic receptor prior to the release of the crystal coordinates of the D 3 receptor, and notwithstanding both screens returned new scaffolds at a similar rate. Since there is the high risk that generally the modelled sequence would reflect the chemotypes of the reference structure, the model was challenged for selectivity, a major bias in comparative modelling studies. It might be expected that screened compounds should retain pharmacology very similar to known binder of the template. However, all the tested compounds had measurable activity against 2 adrenergic receptor although endowing comparable affinity for the dopaminergic subtypes.
An original approach for the generation of 3D-pharmacophore models was developed by Klabunde et al. starting from some GPCRs belonging to class A, employed as reference for the building of a structure-based pharmacophore, further dissected into single-feature pharmacophore elements stored in a pharmacophore building block database. This database was then screened with rules based on chemoprints (motifs in the GPCR sequence to be necessary to recognize and bind a specific ligand feature or fragment) and taken from the sequences alignment of others GPCRs, and assembled to derive different sequence-derived 3D-pharmacophore models with several features and different level of complexity. This protocol was applied in a prospective virtual screening campaign on small molecule ligands of C3AR guided by the similarity between the C3AR1 and the AT 1 receptor, both peptide-binding GPCRs and losartan as additional shape restraint, providing at the end of the study four agonists with a potency below 10 M [265] .
Except for a few studies, fragment-based drug design was not very successful for GPCR but recently de Graaf, et al. [266] developed and validated a virtual screening protocol that combines molecular docking of compounds extracted from ZINC database with protein ligand interaction fingerprints GPCRs FBDD. In such study, fragments were identified as fragment like histamine H 1 receptor ligands and tested displaying affinities ranging from 10 FM to 6 nM.
Ligand-Based In Silico Tools Applied to GPCRs
The increase of experimentally solved GPCRs structures and the consequent increasing quantity of models built by comparative approaches provided over the last 10 years a less profusion above the ligand-based studies in the literature. In this context, insights for the design and development of novel modulators of the interaction between a receptor and its G-protein were achieved by Taylor et al. [267] in a very original research revise targeting a GPCR-activated state via a small molecule binding to the intracellular loops rather than the TMs or the extracellular loops, as done in the majority of the instances.
Several diseases related to psychiatric and neurological disorders might be modulated by novel mechanisms of control through binders of GPCRs acting at allosteric sites. Therefore, their therapeutic potential shown great promise in recent years [268] . Given that capturing the GPCR activated conformation has proven to be difficult [269] , a short peptide of the -subunit of transducin was shown to stabilize the photoactivated state of rhodopsin, a peptidomimetic was design starting from the three-dimensional structure, determined by NMR experiments, of the same subunit in complex with rhodopsin, and served as query in the ligand-based VS where three compounds stabilizing the activated state of rhodopsin were found, supplying a fast and powerful tool in this particular occurrence.
When the structure of the receptor is unknown and, at the same time, when sufficient ligand information is used for the generation of models, the ligand-based screening techniques outperform the molecular docking approach as reported by Evers et al. comparing different virtual screening strategies (molecular docking using GOLD [49] and FlexX-Pharm [53] ligand-based pharmacophore models using CATALYST [26] , or Feature Trees [270] , 3D-similarity searches using FlexS [271] and statistical methods based on 2D molecular descriptors using CATS [74] , MACCS [272] , QikProp [273] , for identifying antagonists of various aminergic GPCRs from virtual libraries and additional drug-like molecules. Indeed, the performance of ligand-based virtual screening procedures depends critically on the amount and quality of ligand information, which is used for the generation of models. Whereas ligand-based models can only reveal binding features, which are already captured by ligands, the inclusion of complementary information from the receptor site allows for a comprehensive understanding of the molecular recognition process.
Ligand-based similarity approaches start from the description of one or several lead structures using one or more structural descriptors, along with similar descriptions of the compounds in a virtual library. These descriptors are often termed "1D" if they describe only extensive quantities such as molecular weight, "2D" if they include topological connectivity, and "3D" if they encode the 3D structure of a molecule. Many metrics exist to measure similarity and distance using these attributes. Their behaviour depends on the set of descriptors used and molecules to compare. Chemical similarity searches for CXCR4 and CCR5 inhibitors have been carried out by Perez-Nueno [92] and Carrieri et al. [274] using QikProp to calculate 1D, 2D, and 3D descriptors for all compounds. The Tanimoto similarity coefficient was calculated using QikSim for all database compounds with respect to a given lead compound and the average of the physicochemical and biological properties of a set of actives.
Regarding CXCR4 entry inhibitors, Perez-Nueno et al. [239] built a pharmacophore model for CXCR4 antagonist inhibitors using MOE and Discovery Studio software suites with four families of known actives, namely the AMD3100 analogues, KRH1636 analogues, dipicolil amine zinc(II) complexes, and the diamine derivatives.
Polypharmacology Tools Applied to GPCRs
The development of target-based affinity profiling methods has taken advantage of the functional coverage of protein families provided by the almost exponential growth in the number of experimentally determined protein structures. Unfortunately, not all of the therapeutically relevant protein families are at present equally covered by 3D structures, largely due to the difficulty of crystallising transmembrane or other cell surface proteins. For example, with over 20000 entries, enzymes are by far the structurally most populated family [275] . In contrast, around 200 structures are available for nuclear receptors and ligand-gated ion channels, whereas only a handful has been resolved for GPCRs. In the latter case, homology modelling techniques are required to complement current low coverage levels of experimentally determined structures with computationally derived structural models [275] .
Drug activity at GPCRs can be defined by physical screening methods and cheminformatic approaches. Through the use of cheminformatics approaches, such as SEA, SHAFTS, or GES, between others, off-target drug actions can be predicted and subsequently validated at GPCRs and other proteins. Such in silico predictions speed the process of defining drug activity at GPCRs, and guide efforts toward testing specific drugs at specific GPCRs. Profiling drugs at the GPCR receptorome using screening and cheminformatic approaches has revealed unexpected insights. These include the identification of toxic targets to avoid, discovery of specific receptor sites for drug activity, and clarification of the polypharmacology of clinically effective drugs. Drug-GPCR profiling has indentified GPCR targets that explain both favorable and adverse drug mechanisms of action [276] . For example, the histamine H 1 receptor is believed to be the major mechanistic target for cetirizine and hydroxyzine, and acebutolol acts through the 1 adrenoceptor, although all these drugs show binding to other GPCRs in in vitro assays. Analysis of the gene-family distribution of targets by drug substance for both small-molecule and biological drugs reveals that more than 50% of drugs target only four key gene families: class I GPCRs, nuclear receptors, ligand-gated ion channels and voltage-gated ion channels. The targets with the most number of drugs approved are the glucocorticoid receptor and the histamine H 1 receptor. Hence, rhodopsinlike GPCRs, certain ion-channel domains and nuclear receptor ligand-binding domains are clear historical examples of druggable domains [277] .
Here we show some examples of successful case studies of GPCR profiling. Using their SEA algorithm, Shoichet's group found unknown associations involving 15 drugs and 23 targets [144] . Most of the predictions involved known aminergic GPCR binders linked to other targets of the same protein family. There were also four drugs crossing target class boundaries. For example, the HIV-1 reverse transcriptase inhibitor Rescriptor was found to bind the histamine H 4 receptor (GPCR). These two targets share no evolutionary history, functional role, or structural similarity. Similarly, the vesicular monoamine transporter (VMAT) inhibitor Xenazine binds two different GPCRs at sub-micromolar concentrations. Despite its use over the last 50 years, Xenazine has not been reported to bind to any GPCR. Also, the selective ion-channel inhibitors Vadilex and RO-25-6981 were predicted and found to bind to GPCRs and to transporters to which they were previously unknown to bind.
Many of Shoichet's predictions could not be confirmed using previously published studies. They therefore tested 30 predictions that were experimentally accessible to them. In radioligand competition binding assays, 23 of these (77%) yielded inhibition constants (K i values) less than 15 mM (lower K i values indicate higher affinity). Fifteen of the 23 were to aminergic GPCRs, and the remainder crossed major receptor classification boundaries. For instance, the 1 antagonist Doralese was predicted and observed to bind to the dopamine D4 receptor (both 1 and D 4 are aminergic GPCRs). Conversely, the HIV-1 reverse transcriptase inhibitor Rescriptor was predicted and observed to bind to histamine H 4 receptor (GPCR); this prediction crosses major target boundaries. For several predictions, they tested multiple receptor subtypes because the MDDR left these unspecified; for example, for a predicted " 1 adrenergic blocker", they tested the drug at 1A , 1B and 1D subtypes; they count these as a single target. In total, 14 drugs bound 23 previously unknown targets, with 13 having sub-micromolar and five having sub-100nM affinities. Indeed, 10 of the 14 drugs reported by Shoichet group were active against aminergic GPCRs, and so their cross-activities against other aminergic GPCRs have some precedent. Finally, although most of the drugs were active at their predicted off-targets, one-third was not. These are examples of the false-positives to which SEA method is susceptible.
In another study using SEA, Keiser et al. [128] point out that related drugs and biological messengers can bind to receptors that appear unrelated by many bioinformatics metrics. For instance, serotonin and serotonergic drugs bind to GPCRs such as the 5-hydroxytryptamine subtypes 1, 2 and 4-7 (5-HT 1,2,4-7 ), but also to an ion channel, the 5-HT 3A receptor. Ionotropic and metabotropic 5-HT receptors are unrelated by sequence and structure, yet both are involved in the pharmacological effects of serotonergic drugs. Similarly, the well-known opioid methadone binds not only to the J-opioid receptor, a GPCR, but also to the N-methyl-D-aspartic acid (NMDA) receptor, an ion channel, and both are thought to be involved in the drug's biological activity. In the minimum spanning trees resulting from their analysis, many proteins with related functions cluster together. Thus, ion channels and GPCRs that have no obvious sequence or structure similarity are linked quantitatively based on their bioactive ligands.
Shoichet's group also show in another study that the pharmacology networks that they calculated complement those more familiar from bioinformatics and reveal relationships among targets that would be obscure on the basis of sequence or structural similarities alone. For instance, some drugs acting on J-opioid receptors were found to resemble those acting on M 3 muscarinic receptors, despite the differences between these receptors, leading to the prediction that the opioid methadone will antagonize M 3 muscarinic receptors. Similarly, a drug acting on protein biosynthesis was predicted to bind to adrenergic receptors, even though the ribosome and adrenergic GPCRs are biologically unrelated. Shoichet's group found that there were many more cases where targets highly related by sequence were unrelated by ligands, and many cases where receptors unrelated by sequence were highly related by ligands. For instance, the opioid receptors are related to many serotonergic receptors; both are GPCRs with many structural similarities. However, their ligands bear little relationship. On the other hand, the metabatropic and ionotropic glutamate receptors bear no sequence similarity, the one being GPCRs, the other ion channel, but their ligands are often highly related. Overall, only 20-30% of the targets were highly related by both sequence and ligand similarity. Shoichet et al. explain the differences between ligand-set similarity and sequence identity. Sequence identity is measured across an entire protein, whereas ligand similarity is local. The GPCRs, for example, are conserved in overall sequence and most share a common ancestry, but many recognize unrelated ligands. On the other hand, the chemoinformatics methods recognize pharmacologically relevant relationships that are often obscure to bioinformatics approaches, owing to ligand-set similarity. For instance, the 5-HT 3 ionotropic and the metabotropic 5-HT 4 serotonergic receptors are related by ligand-based methods, as are the ionotropic glutamate receptors (AMPA, NMDA, and Kainate) and the glutamate metabotropic receptors, for example, mGluR4. By sequence and structure, of course, there is little relationship between these ion channels and GPCRs.
Schneider et al. used self-organizing maps in a polypharmacology context by projecting aspirin on a SOM trained on approved drugs and leads [278] . Self-organizing maps were used to predict a new target for aspirin, tyrosine phosphatase 1B. Noeske et al. also used self-organizing maps to find new targets for known antagonists of metabotrobic glutamate receptor subtypes 1 and 5 [279] . Their SOM predicted other GPCRs, such as dopamine D 2 and D 3 , muscarinic acetylcholine receptors and histamine H 1 as possible targets, which were experimentally verified with IC 50 values between 5 and 100 M.
Gregori-Puigjané and Mestres successfully applied drugtarget networks on data obtained from an in silico target profiling of 767 drugs on 684 targets [280] . The network showed that some aminergic GPCRs were highly connected to NMDA, sigma and opioid receptors, despite any phylogenetic relationships, which was confirmed by annotated examples from literature. Moreover, in their work on the topology of drug-target interaction networks, Mestres et al. [182] point out that while many of the large hydrophilic drugs are enzyme inhibitors, the majority of the small hydrophobic drugs interact with GPCRs, an indication that the degree of drug-target interactions may vary among target families. They constructed a drug-target network for GPCRs containing 2646 interactions between 396 drugs and 106 targets. This network resulted in an average number of interactions per drug of 6.7, with a projected value of 10.0. Compared to the drug-target networks obtained for other three target families (enzymes, ion channels/transporters, nuclear receptors), the topology of their GPCRs network is visually more dense and interconnected, with many targets collapsed in the centre of the network. They obtained a remarkable convergence of the results. From the analysis of drug properties, it was observed that small hydrophobic drugs appear to be significantly more promiscuous than large hydrophilic drugs, whereas from the analysis of target families, the drug-target interaction network composed by drugs targeting GPCRs was found to be significantly more connected than any of the networks derived for the other target families. Both findings converge when realising that small hydrophobic drugs are known to interact primarily with GPCRs, whereas the majority of the large hydrophilic drugs appear to be enzyme inhibitors.
Yabuuchi et al. constructed a predictive model based on 5207 compound-protein interactions (CPIs), including 317 GPCRs and 866 GPCR ligands, from the GLIDA database [281] . They evaluated the ability of the CGBVS method to predict the polypharmacology of 2 -adrenergic receptor by attempting to identify novel 2 -adrenergic receptor ligands from the above ligand data set. They trained an SVM classifier using all 5207 CPIs, and applied their CGBVS approach to predict scores for the 866 known GPCR ligands. They ranked the prediction scores for the interactions of 826 reported GPCR ligands (excluding 40 already known 2 -adrenergic receptor ligands) with 2 -adrenergic receptor, and then analyzed the 50 highest-ranked compounds in greater detail. This search identified 15 of the top 50 compounds as known 2 -adrenergic receptor ligands. These 2 -adrenergic receptor ligands already reported in the literature were excluded from analysis, and the remainder 35 ligands were tested in in vitro binding assays. From those, 21 were commercially available, and of these 21, 11 were not previously reported but were discovered to bind to 2 -adrenergic receptor.
To identify possible polypharmacological relationships among GPCRs, Yabuuchi et al. constructed polypharmacology maps [164] , first based on multiple interactions between GPCRs and their ligands predicted by CGBVS, and second based on previously reported interactions. CGBVS predicted many unexpected multiple interactions between GPCRs and ligands, including, interestingly, interactions shared by members of distantly related subfamilies. To better understand the propensity for ligand promiscuity, they extracted chemical substructures characteristic of the putatively promiscuous ligands. Their analysis show that tertiary amine and sulfur-containing heterocycles are recurring substructures in the promiscuous ligands when compared with selective ligands. For example, these substructures are typically seen in antidepressants used to treat depression and anxiety disorders, which interact promiscuously with a range of dopamine and serotonin receptors [282] . This observation suggests that the ligands containing such substructures can be non-selective.
Van der Horst et al. applied substructure mining to GPCR ligands [162] . In their study, they conducted frequent substructure mining to identify structural features that discriminate between ligands that do bind to GPCRs and those that do not. In most cases, particular chemical representations resulted in the most significant substructures. Alkane amine substructures were identified as most important for GPCR ligands, e.g. the butylamine substructure, often linked to an aromatic system. Hierarchical analysis of targeted GPCRs revealed well-known motives and new substructural features. One example is the imidazole-like substructure common for the histamine binding receptor ligands. Another example is the planar ring system consisting of a fused fiveand six-membered ring (indole-like substucture) common for the serotonin receptor ligands. Van der Horst et al. also developed a classification of GPCRs purely based on their ligands, complementing sequence-based phylogenetic classifications of these receptors [163] . They hierarchically classified targets into phylogenetic trees, for both sequence space and ligand (substructure space). Its GPCR classification reveals relationships that were unnoticed with conventional phylogeny. The overall organization of the sequence-based tree and substructure-based tree was similar. In particular, the adenosine receptors cluster together as well as most peptide receptor subtypes (e.g. opioid, somatostatin) and adrenoceptor subtypes. In ligand space, the prostanoid and cannabinoid receptors are more distant from the other targets, whereas the tachykinin receptors, the oxytocin receptor, and serotonin receptors are closer to the other targets, which is indicative for ligand promiscuity. In 93% of the receptors studied, de-orphanization of a simulated orphan receptor using the ligands of related receptors performed better than random (Area Under the Curve (AUC) > 0.5) and for 35% of receptors de-orphanization performance was good (AUC > 0.7).
Jacob et al. [161, 166] applied their support vector machine method to GPCRs. They show that the prediction in the chemogenomics framework outperforms state-of-the-art individual ligand-based methods in accuracy both for receptor with known ligands and without known ligands. They are able to predict ligands of orphan GPCRs with an estimated accuracy of 78.1%.
Weill et al. [175] applied their protein-ligand fingerprint to mine chemogenomic space onto G protein-coupled receptors and their ligands. Whereas ligand properties are represented by standard descriptors, protein cavities are encoded by a fixed length bit string describing pharmacophoric properties of a definite number of binding site residues. They gave particular attention to set up data sets of very diverse protein-ligand pairs covering as exhaustively as possible both ligand and target spaces. They trained several machine learning classification algorithms on two sets of roughly 200000 receptor-ligand fingerprints with a different definition of inactive decoys. Cross-validated models showed excellent precision (>0.9) in distinguishing true from false pairs with a particular preference for support vector machine classifiers. They show that the ability to recover true GPCR ligands (ligand prediction mode) or true GPCRs (receptor prediction mode) depends on multiple parameters: the molecular complexity of the ligands, the chemical space from which ligand decoys are selected to generate false proteinligand pairs, and the target space under consideration. In most cases, predicting ligands is easier than predicting receptors. Although receptor profiling is possible, it probably requires a more detailed description of the ligand-binding site.
In another study [283] , the MDDR database was used as a source of ligands annotated to the four major target classes, namely, enzymes, GPCRs, nuclear receptors and ligandgated ion channels. The resulting ligand-target classification scheme was subsequently used for searching for structures binding to dopamine D 2 , all dopamine receptors, and all amine-binding class A GPCRs using dopamine D 2 -binding compounds as a reference set.
Paolini et al. show in their network pharmacology work [142] that the different definitions of promiscuity highlight different effects, although the same target classes (aminergic GPCRs, cytochrome P450s and protein kinases) appear at the top positions. They illustrate the cumulative strength of intragene as well as inter-gene family connections. Aminergic GPCRs and protein kinases exhibit the greatest intra-gene and inter-gene family promiscuity.
Other successful case studies of GPCR profiling include the identification of the 5-HT 2B receptor as a site of cardiacvalve toxicity (this receptor is now routinely avoided by screening during drug development), profiling the hallucinogen salvinorin A at GPCRs identified the opioid receptor as the essential site of drug action (this has allowed the development of a new class of potent opioid receptor agonists), and profiling atypical antipsychotic drugs has determined that these drugs display complex polypharmacology across many GPCRs, which may explain their superior clinical efficacy [276] .
Overall, the evidence that many drugs exhibit polypharmacology at GPCRs may open a new systems-based approach to GPCR drug discovery that incorporates the concept of network pharmacology. This approach would seek to understand the role of receptor networks of drug action in biological systems and use this information to inform and guide drug development. Discovering drug activity among the GPCRs will remain an essential tool for such future efforts [276] .
TRADITIONAL VIRTUAL SCREENING VS MULTI-TARGET SCREENING
Systems-level perspectives on how small molecules interact with the biological machinery are becoming increasingly important in medicinal chemistry [168] . Identifying drug targets and predicting new drug-target interactions is challenging. Until recently, drug development programmes would typically aim to design a small molecule which would be highly selective for a given protein target. However, it is becoming increasingly apparent that many existing drugs interact with multiple proteins [144] . Hence, "chemogenomic" approaches are necessary to understand and exploit such polypharmacological effects [169] .
There is currently a desperate shortage of new drug molecules in the pharmaceutical pipeline. One way to address this problem is to exploit existing structural knowledge more effectively to re-target known drug molecules against new proteins. Another more conventional way to develop new drugs is to find new compounds which are similar to existing drug molecules. For this, several VS approaches have been proposed, but these all have limitations. Indeed, it has recently been shown that the most recent 3D VS approaches often give little or no benefit over 1D and 2D fingerprint methods that were developed many years ago [284] . Nonetheless, to be able to predict off-target polypharmacological effects, we need very fast and sensitive methods for comparing multiple small molecules and protein pockets, such as those in this review and future improvements of them.
FUTURE DIRECTIONS AND
In the last decade, strategies for drug repositioning have become attractive [285] [286] [287] [288] . Of course, a good candidate for repositioning would be a promiscuous multi-functional multi-potent ligand [289] . In principle, promiscuous drugs might be more indicated for the treatment of those pathologies requiring polypharmacological treatment (e.g., CNS disorders, cardiovascular diseases, and metabolic syndrome), with the main advantages over administering multiple single drugs stemming from the possibility of tailoring potentially different degrees of bioavailability, pharmacokinetics, and metabolism in one molecular entity. Furthermore, multipotent drugs would offer the simplification of the therapeutic regimen thus favouring compliance [290] . GPCRs play a pivotal role in a number of physiological processes and are mainly involved in disorders requiring the administration of several distinct drugs. GPCR ligands often display polypharmacology thus approaching the ideal of "magic shotguns" [276] . Several recent reports indicate that VS approaches can be successful in the early steps of drug repositioning [291] and, when applied to GPCRs, might offer an invaluable way to improve our therapeutic panoply for the treatment of several challenging diseases.
The present review collects studies which demonstrate the applicability of in silico methods for polypharmacology analysis and drug repurposing. Although some polypharmacology approaches have already been applied successfully, there is still much scope for improvement and further development. Ultimately, polypharmacology approaches need to be able to work rapidly, robustly, and at a highly predictive level. In a systems pharmacology view of drug action, a drug interacts with multiple primary and secondary targets. These targets exist within a complex network which can mediate the response to the drugs leading to both therapeutic and adverse effects. Hence, there is a need to develop and improve the already existent computational approaches that aim to predict drug-target binding and, therefore, predict off-target binding and possible adverse effects (see Fig. 5 ).
Another promising area in network-based prediction of drug targets is the ability to predict combinations of targets, or protein complexes, which will prove to be most efficacious and safe when targeted together. Since networks emphasize the relationships between proteins, they can suggest pairs or groups of drug targets that can work well together to treat a disease. Hence, systems pharmacology approaches like those reviewed here are required in order to be able to study combinations of drugs against disease mechanisms which are not blocked by a single ligand. The global understanding of diseases and drug effects based on network relationships between drug targets can also allow re-purposing of existing drugs with known targets for an individual use or use in combination therapies for different diseases. Such reuse has the advantage that the safety of individual drugs has already been established. Thus, combination therapies using previously approved drugs could lead to safer and more efficient treatments. The ability to better understand and predict synergistic effects of drug combinations is one of the enticing promises of systems pharmacology.
Overall, we believe that future work on developing computational approaches aiming to join systems pharmacology with the classical virtual screening paradigm will be key to a "systems-level" approach to drug design. Because additional off-targets can mediate effects through distinct effector pathways to lead to other side effects and other adverse events, adopting a "systems-level" approach to polypharmacology relationships, specific drug information, targeted biological data, and specific disease information will provide a much more rational way to select compounds for testing than simply selecting a given percentage of hits in a classical virtual screening exercise.
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